Dashboard
Manage Tickers

KALVKalVista Pharmaceuticals, Inc.

Nasdaq kalvista.com


$ 12.15 $ -0.04 (-0.33 %)    

Friday, 03-May-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 12.13
$ 12.19
$ 0.00 x 0
$ 0.00 x 0
$ 11.95 - $ 12.40
$ 7.21 - $ 16.88
199,656
na
421.19M
$ 1.00
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-11-2024 01-31-2024 10-Q
2 12-07-2023 10-31-2023 10-Q
3 09-07-2023 07-31-2023 10-Q
4 07-07-2023 04-30-2023 10-K
5 03-09-2023 01-31-2023 10-Q
6 12-08-2022 10-31-2022 10-Q
7 09-08-2022 07-31-2022 10-Q
8 07-07-2022 04-30-2022 10-K
9 03-10-2022 01-31-2022 10-Q
10 12-09-2021 10-31-2021 10-Q
11 09-09-2021 07-31-2021 10-Q
12 07-13-2021 04-30-2021 10-K
13 03-11-2021 01-31-2021 10-Q
14 12-10-2020 10-31-2020 10-Q
15 09-14-2020 07-31-2020 10-Q
16 07-01-2020 04-30-2020 10-K
17 03-10-2020 01-31-2020 10-Q
18 12-03-2019 10-31-2019 10-Q
19 09-09-2019 07-31-2019 10-Q
20 07-16-2019 04-30-2019 10-K
21 03-14-2019 01-31-2019 10-Q
22 12-14-2018 10-31-2018 10-Q
23 09-14-2018 07-31-2018 10-Q
24 07-30-2018 04-30-2018 10-K
25 03-16-2018 01-31-2018 10-Q
26 12-14-2017 10-31-2017 10-Q
27 09-14-2017 07-31-2017 10-Q
28 07-27-2017 04-30-2017 10-K
29 03-16-2017 01-31-2017 10-Q
30 11-08-2016 09-30-2016 10-Q
31 08-12-2016 06-30-2016 10-Q
32 05-12-2016 03-31-2016 10-Q
33 03-30-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-21-2015 03-31-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-kalvista-pharma-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on KalVi...
05/03/2024 19:44:50

HC Wainwright & Co. analyst Andrew Fein maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target f...

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
05/01/2024 16:14:49

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-pharmaceuticals-announced-its-strategic-plans-for-fiscal-year-2025-beginning-may-1-including-for-sebetralstat-the-companys-investigational-novel-oral-plasma-kallikrein-inhibitor-for-the-on-demand-treatment-of-hereditary-angioedema
Kalvista Pharmaceuticals Announced Its Str...
05/01/2024 10:38:07

needham-reiterates-buy-on-kalvista-pharma-maintains-35-price-target
Needham Reiterates Buy on KalVista Pharma,...
04/11/2024 10:07:50

Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

kalvista-pharmaceuticals-presented-multiple-analyses-of-the-relationship-between-the-time-to-attack-treatment-and-the-effects-delays-in-treatment-have-on-clinical-outcomes-of-hereditary-angioedema-at-the-2024-haei-regional-conference-americas
KalVista Pharmaceuticals Presented Multipl...
03/18/2024 10:46:21

hc-wainwright--co-reiterates-buy-on-kalvista-pharma-maintains-24-price-target
HC Wainwright & Co. Reiterates Buy on KalV...
03/12/2024 10:56:25

HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $24 price target.

kalvista-pharmaceuticals-announced-the-uk-medicines-and-healthcare-products-regulatory-agency-has-awarded-the-promising-innovative-medicine-designation-for-sebetralstat-for-on-demand-treatment-of-hereditary-angioedema
KalVista Pharmaceuticals Announced The UK ...
03/12/2024 10:38:04

needham-maintains-buy-on-kalvista-pharma-maintains-35-price-target
Needham Maintains Buy on KalVista Pharma, ...
03/11/2024 19:52:58

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $35 price target.

recap-kalvista-pharma-q3-earnings
Recap: KalVista Pharma Q3 Earnings
03/11/2024 13:30:06

kalvista-pharma-q3-eps-084-misses-077-estimate
KalVista Pharma Q3 EPS $(0.84) Misses $(0....
03/11/2024 10:42:25

KalVista Pharma (NASDAQ:KALV) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0...

kalvista-pharmaceuticals-says-it-will-present-hae-attack-journey-data-at-2024-haei-regional-conference-americas
KalVista Pharmaceuticals Says It Will Pres...
03/08/2024 11:44:20

kalvista-pharmaceuticals-announced-that-benjamin-l-palleiko-the-current-president-cbo-and-cfo-has-been-appointed-as-chief-executive-officer-and-a-director-of-the-company-effective-immediately
KalVista Pharmaceuticals Announced That Be...
03/07/2024 11:31:43

kalvista-presents-additional-data-on-its-phase-3-konfident-trial-for-sebetralstat
KalVista Presents Additional Data On Its P...
02/26/2024 11:36:37

The company 94% of attacks required only one dose to achieve primary endpoint, Further analyses demonstrate efficacy across all...

kalvista-says-uk-mhra-awarded-innovation-passport-for-sebetralstat-an-investigational-novel-oral-plasma-kallikrein-inhibitor-for-on-demand-treatment-of-hereditary-angioedema
KalVista Says UK MHRA Awarded Innovation P...
02/20/2024 11:56:10

The Innovation Passport is the first step in the UK's Innovative Licensing and Access Pathway (ILAP), which is designed to ...

kalvista-pharmaceuticals-says-it-will-present-phase-3-sebetralstat-data-at-the-2024-american-academy-of-allergy-asthma--immunology-annual-meeting
KalVista Pharmaceuticals Says It Will Pres...
02/16/2024 11:33:18

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
02/15/2024 13:05:57

kalvista-pharmaceuticals-has-priced-the-public-offering-of-702m-shares-at-1525share-and-pre-funded-warrants-to-purchase-348m-shares-for-gross-proceeds-of-around-1601m
KalVista Pharmaceuticals Has Priced The Pu...
02/15/2024 11:32:19

kalvista-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants
KalVista Pharmaceuticals Announces Propose...
02/14/2024 21:40:33

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
02/14/2024 21:31:06

citigroup-to-rally-over-19-here-are-10-top-analyst-forecasts-for-wednesday
Citigroup To Rally Over 19%? Here Are 10 T...
02/14/2024 12:49:58

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION